What is Affibody's ABY-271 trial testing?

Affibody's ABY-271 trial is evaluating a radioligand therapy candidate for HER2-positive metastatic breast cancer.

What were the key findings from the first part of the Phase I trial?

The initial patient data demonstrated targeted tumor activity and low uptake in vital organs, particularly the kidneys.

When will Affibody's ABY-271 trial move to the next phase?

Affibody anticipates beginning the second part of the trial in the first half of 2026.

Home / Health / Breast Cancer Trial Advances with Promising Early Results

Breast Cancer Trial Advances with Promising Early Results

17 Dec, 2025

•

Summary

Trial Review Committee recommends advancing ABY-271 to Phase I trial second part.
Therapy demonstrated targeted tumor activity and low kidney uptake.
Next phase will test higher radioactivity levels and additional doses.

Breast Cancer Trial Advances with Promising Early Results

Affibody's investigational radioligand therapy, ABY-271, has earned a recommendation from its Trial Review Committee to advance into the second part of its Phase I clinical trial. This progression is for patients diagnosed with HER2-positive metastatic breast cancer.

Initial patient data from the trial's first cohort revealed compelling results, including targeted tumor activity and notably low uptake in kidneys and other critical organs. These findings support the therapy's potential efficacy and safety profile.